Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Antiviral Efficacy of Iota-Carrageenan Lozenges in Treating Acute Viral Pharyngitis: A Randomized Controlled Study

Karna et al., Journal of Neonatal Surgery, doi:10.47338/jns.v13.1432
Dec 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Non-COVID-19 RCT 180 patients with acute viral pharyngitis, predominantly caused by human rhinovirus (HRV), showing symptom improvement and viral load reduction with iota-carrageenan lozenges compared to placebo. Patients receiving lozenges (6 daily for up to 10 days) reported faster symptom relief based on Jackson's Total Symptom Score, particularly between days 2 and 4. Human rhinovirus (HRV)-positive participants experienced a 90.2% viral load reduction versus 72.0% in the placebo group by day 5. Adverse events were minimal and similar across groups, with mild throat irritation being most common.
Iota-carrageenan works by binding to viral particles and preventing attachment to host cells. This mechanism is not virus-specific and has shown broad-spectrum activity against other respiratory viruses, including coronaviruses and SARS-CoV-2, in preclinical studies. Lozenges provide targeted delivery to the throat, a key site of viral replication in early COVID-19. This localized action could help reduce viral load in the upper respiratory tract, potentially impacting transmission and disease progression.
Karna et al., 30 Dec 2024, Double Blind Randomized Controlled Trial, placebo-controlled, peer-reviewed, 2 authors.
This PaperIota-carragee..All
Antiviral Efficacy of Iota-Carrageenan Lozenges in Treating Acute Viral Pharyngitis: A Randomized Controlled Study
Dr Samiksha Karna, Dr Abhay D Havle
Journal of Neonatal Surgery, doi:10.52783/jns.v13.1432
Iota-carrageenan, acute viral pharyngitis
References
Cherian, Potdar, Jadhav, Yadav, Gupta et al., Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India, bioRxiv, doi:10.1101/2021.04.22.440932
Collier, Marco, Ferreira, Meng, Datir et al., Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies, Nature, doi:10.1038/s41586-021-03461-y
Davies, Abbott, Barnard, Jarvis, Kucharski et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, doi:10.1126/science.abg3055
Galloway, Paul, Maccannell, Johansson, Brooks et al., Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States, MMWR Morb. Mortal. Wkly. Rep, doi:10.15585/mmwr.mm7003e2
Hou, Okuda, Edwards, Martinez, Asakura et al., SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract, Cell, doi:10.1016/j.cell.2020.05.042
Kim, Jang, Soh, Lee, Lee, The Impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 pseudovirus, Viruses, doi:10.3390/v13040633
Korber, Fischer, Gnanakaran, Yoon, Theiler et al., Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell, doi:10.1016/j.cell.2020.06.043
Little, Read, Amlôt, Chadborn, Rice et al., Reducing risks from coronavirus transmission in the home-the role of viral load, BMJ, doi:10.1136/bmj.m1728
Meng, Kemp, Papa, Datir, Ferreira et al., Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7, Cell Rep, doi:10.1016/j.celrep.2021.109292
Meselson, Droplets and aerosols in the transmission of SARS-CoV-2, N. Engl. J. Med, doi:10.1056/NEJMc2009324
Mwenda, Saasa, Sinyange, Busby, Chipimo et al., Detection of B.1.351 SARS-CoV-2 Variant Strain-Zambia
Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization, Nature, doi:10.1038/s41586-021-03777-9
Tegally, Wilkinson, Giovanetti, Iranzadeh, Fonseca et al., Detection of a SARS-CoV-2 variant of concern in South Africa, Nature, doi:10.1038/s41586-021-03402-9
Volz, Mishra, Chand, Barrett, Johnson et al., Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England, Nature, doi:10.1038/s41586-021-03470-x
Wang, Casner, Nair, Wang, Yu et al., Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization, bioRxiv, doi:10.1101/2021.03.01.433466
Wibmer, Ayres, Hermanus, Madzivhandila, Kgagudi et al., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma, Nat. Med, doi:10.1038/s41591-021-01285-x
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit